Publications
5891 Results
- Journal / Conference
- Cancer Communications Aug;45(8):976-986
- Year
- 2025
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID40402690
- PMC
- PMC12365539
- Study Number(s)
- S1609
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort
- Journal / Conference
- ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Impact of Sirtuin genes expression on first-line treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance)
- Journal / Conference
- ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
The prognostic impact of SLFN11 gene expression in metastatic colorectal cancer (mCRC) (Alliance)
- Journal / Conference
- ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Clinical and Molecular Characterization of FAP and SPP1 in Colorectal Cancer, CALGB (Alliance)/SWOG 80405 and Real-World Data
- Journal / Conference
- ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Expression of metabolic genes affects patients (pts) outcomes in metastatic colorectal cancer (mCRC): data from CALGB/SWOG 80405 (Alliance)
- Journal / Conference
- ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Evaluation of CSF1R as a Prognostic and Predictive Biomarker in Colorectal Cancer
- Journal / Conference
- Society for Surgical Oncology Annual Meeting (March 27-29, 2025, Tampa, FL)
- Year
- 2025
- Research Committee(s)
- Palliative Care
- Study Number(s)
- S1316
Lessons Learned from SWOG S1316: Optimizing Surgical Trial Design for Malignant Bowel Obstruction
- Journal / Conference
- ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/EA2186
Effect of baseline geriatric and quality of life assessments on treatment outcomes in ECOG-ACRIN EA2186 (GIANT) - A randomized phase II study of Gemcitabine and NabPaclitaxel compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (NCT04233866)
- Journal / Conference
- ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA), abstract 666
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/A021602
Efficacy and Safety of Cabozantinib for Advanced Gastrointestinal Neuroendocrine Tumors (NET) after Progression on Prior Therapy: A Subgroup Analysis of the Phase III CABINET Trial (Alliance A021602)
- Journal / Conference
- ASCO GU Cancers Symposium (Feb 13-15, 2025, San Francisco, CA), poster
- Year
- 2025
- Research Committee(s)
- Genitourinary